Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Reliant Rehabilitation Sold to H.I.G. Capital
Rehabilitation deals aren’t made public very frequently, but when the target is big enough, we hear about them. That was the case when H.I.G. Capital announced the closing of its acquisition of Reliant Rehabilitation Holdings, Inc., a leading provider of therapy services, including physical, occupational and speech, to skilled nursing facilities. Headquartered in Plano, Texas, Reliant is one of the largest providers of contract therapy services in the United States. It uses a proprietary care model that emphasizes early intervention/assessment, properly designed clinical care plans and pathways to improve patients’ functional levels. In this time of critical labor shortages in many... Read More »
Amicus Therapeutics Buys Gene Therapy Company
Amicus Therapeutics (NASDAQ: FOLD) is focused on rare and orphan diseases. So it’s no head-scratcher that the Cranbury, New Jersey-based biotech agreed to shell out $100 million to acquire Celenex. a clinical-stage gene therapy company in Columbus, Ohio. Celenex’ lead programs in CLN6, CLN3 and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devestating diseases. Batten disease, also known as Neuronal Ceroid Lipofuscinosis (NCL), is a family of rare disorders that can be life-threatening and debilitating, with high unmet need. With this acquisition, Amicus gains the worldwide development and commercial rights for 10 gene therapy programs... Read More »
This Is (Not) Spinal Tap
We’ve seen a rash of deals for all things spinal in recent weeks, from Stryker Corp.’s (NYSE: SYK) $1.4 billion deal for K2M Group (NASDAQ: KTWO) to IZI Medical’s acquisition of Benvenue Medical’s vertebral augmentation systems. What’s the occasion? Well, it’s that time of year when the big medical conferences loom. The Society for Minimally Invasive Spine Surgery (SMISS) took place in Las Vegas between September 6 and 8, and the North American Spine Society (NASS) do is about to get under way in Los Angeles from September 26 through the 29. On the smaller scale of targets is Maxim Surgical, based in Richardson, Texas, which was acquired by Fuse Medical... Read More »
Health Care M&A Deals, Week Ending September 14, 2018
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Fulcrum Equity Partners Life of Purpose Treatment Centers N/A 360 Behavioral Health Passport to Adaptive Living N/A Biotechnology Acquirer Target Price Allergan plc Bonti, Inc. $195 million Boehringer Ingelheim... Read More »
DW Healthcare Partners Exits Rehab and Enters Behavioral Health
DW Healthcare Partners has had a busy summer, buying a healthcare staffing company and a behavioral health platform, then selling its rehabilitation business. In June, the firm announced its investment in Aequor Healthcare Services in Piscataway, New Jersey, the sixth investment made by DW Healthcare Partners Fund IV, LP. Aequor specializes in healthcare and clinical staffing by providing physicians, therapists, nurses, technologists and allied healthcare professionals to hospital systems, nursing homes, home care providers, clinics, school systems, laboratories, and pharmaceutical/life sciences organizations nationwide. In August, it acquired California Psychcare, a behavioral services... Read More »
Welltok Strikes Again, Buying WellPass
Welltok, a portfolio company of New Enterprise Associates since 2013, has boosted its consumer health platform, CafeWell, with the acquisition of WellPass. WellPass was formed in 2017 through the merger of Sense Health and Voxiva. The latter worked with many large payers and organizations on mobile and digital health products. Sense Health focuses on Medicaid care managers. Wellpass has created interactive, popular text-based programs such as Text4Baby, Text2Quit and Care4Life, and works with a roster of Medicaid plans, state Medicaid agencies and departments of health, as well as providers and pharmaceutical companies. The acquisition will allow Wellpass’ current clients to more... Read More »
Allergan Doubles Down on Aesthetics
September 14 was a big day for Allergan plc’s (NYSE: AGN) medical aesthetics business. The company announced its acquisition of Bonti, Inc., a privately held clinical-stage biotech that develops novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Later that same day, Allergan hosted a Medical Aesthetics Day in New York, at which its chief commerical officer, Bill Meury, said the company expects the unit to generate between $7 billion and $8 billion in sales by 2025. The business unit generated $3.8 billion in 2017. Allergan’s Medical Aesthetics unit includes the famous neurotoxin Botox (onabotulinumtoxinA), which was first approved in 1989 and... Read More »
Health Care M&A Deals, Week Ending September 7, 2018
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price United Therapeutics Corp. Collaboration on pulmonary hypertension products $45 million Kwang Dong Pharmaceutical Co., Ltd. License to ATB-346 $9.8 million Biohaven Pharmaceutical Holding Company Ltd. License to AZD3241 N/A Shire plc Sanaplasma AG N/A... Read More »
Summertime Sales from Novartis
It’s been a busy summer for Novartis AG (NYSE: NVS). The Swiss drug-maker has sold off a few assets, one at a loss. On August 31, Mylan NV (NYSE: MYL) acknowledged that it paid $463 million for Novartis’ cystic fibrosis products. Novartis sold the worldwide rights to commercialize its cystic fibrosis products TOBI Podhaler (tobramycin inhalation powder) and TOBI (tobramycin solution for inhalation). Mylan expects to pay $240 million this year, with the rest coming later. Then on September 6, Novartis announced the sale of certain assets in its Sandoz U.S. portfolio, specifically the Sandoz dermatology business and generic oral solids portfolio. It comprises approximately 300... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
